Amyloidosis- Where are we now and where are we heading?

Archives of Pathology and Laboratory Medicine

Volumn 134, Issue 4, 2010, Pages 545-551

  Picken, Maria M ^a  

^a LOYOLA UNIVERSITY MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMYLOID; COLORING AGENT; CONGO RED;

AMYLOIDOSIS; ARTICLE; CLASSIFICATION; CLINICAL PROTOCOL; GENETIC SCREENING; GENETICS; HUMAN; METABOLISM; STAINING; STANDARD; SUBCUTANEOUS FAT;

AMYLOID; AMYLOIDOSIS; CLINICAL PROTOCOLS; COLORING AGENTS; CONGO RED; GENETIC TESTING; HUMANS; STAINING AND LABELING; SUBCUTANEOUS FAT;

EID: 77950486751     PISSN: 00039985     EISSN: 15432165     Source Type: Journal    
DOI: None     Document Type: Article

References (56)

1. Westermark P, Benson MD, Buxbaum JN, et al. A primer of amyloid nomenclature. Amyloid. 2007;14(3):179-183. (Pubitemid 47262691)
2. Picken MM. New Insights into systemic amyloidosis: the importance of type diagnosis. Curr Opinion Nephrol Hypertens. 2007;16(3):196-203.
3. Benson MD, James S, Scott K, Liepnieks JJ, Kluve-Beckerman B. Leukocyte chemotactic factor 2: a novel renal amyloid protein. Kidney Int. 2008;74(2):18-22. (Pubitemid 351915083)
4. Sanchorawala V, Skinner M, Quillen K, et al. Long-term outcome of patients with AL amyloidosis treated with high-dose melphalan and stem cell transplantation. Blood. 2007;110(10):3561-3563. (Pubitemid 350159622)
5. Lacy MQ, Dispenzieri A, Hayman SR, et al. Autologous stem cell transplant after heart transplant for light chain (AL) amyloid cardiomyopathy. J Heart Lung Transplant. 2008;27(8):823-829. (Pubitemid 351768166)
6. Comenzo RL, Steingart RM, Cohen AD. High-dose melphalan versus melphalan plus dexamethasone for AL amyloidosis. N Engl J Med. 2008;358(1):92.
7. Audard V, Matignon M, Weiss L, et al. Successful long-term outcome of the first combined heart and kidney transplant in a patient with systemic AL amyloidosis. Am J Transplant. 2009;9(1):236-240.
8. Lachmann HJ, Goodman HJ, Gilbertson JA, et al. Natural history and outcome in systemic AA amyloidosis. N Engl J Med. 2007;356(23):2361-2371.
9. Moser C, Pohl G, Haslinger I, et al. Successful treatment of familial Mediterranean fever with Anakinra and outcome after renal transplantation. Nephrol Dial Transplant. 2009;24(2):676-678.
10. Herlenius G, Wilczek HE, Larsson M, et al. Ten years of international experience with liver transplantation for familial amyloidotic polyneuropathy: results from the Familial Amyloidotic Polyneuropathy World Transplant Registry. Transplantation. 2004;77(1):64-71. (Pubitemid 38116874)
11. Magy N, Liepnieks JJ, Yazaki M, et al. Renal transplantation for apolipoprotein AII amyloidosis. Amyloid. 2003;10(1):224-228. (Pubitemid 38117507)
12. Gillmore JD, Stangou AJ, Lachmann HJ, et al. Organ transplantation in hereditary apolipoprotein AI amyloidosis. Am J Transplant. 2006;6(10):2342-2347. (Pubitemid 44359419)
13. Mousson C, Heyd B, Justrabo E, et al. Successful hepatorenal transplantation in hereditary amyloidosis caused by frame-shift mutation in fibrinogen A alpha-chain gene. Am J Transplant. 2006;6(3):632-635. (Pubitemid 43382153)
14. Dember LM, Hawkins PN, Hazenberg BP, et al. Eprodisate for the treatment of renal disease in AA amyloidosis. N Engl J Med. 2007;356(23):2349-2360. (Pubitemid 46883769)
15. Sekijima Y, Dendle MA, Kelly JW. Orally administered diflunisal stabilizes transthyretin against dissociation required from amyloidogenesis. Amyloid. 2006; 13(4):236-249. (Pubitemid 44764463)
16. Berk J, Bisbee J, Kelly J, et al. Clinical trial for TTR amyloidosis using diflunisal. Amyloid. 2006;13(suppl 1):11.
17. Dember LM. Modern treatment of amyloidosis: unresolved questions. J Am Soc Nephrol. 2009;20(3):469-472.
18. Dember LM. Amyloidosis-associated kidney disease. J Am Soc Nephrol. 2006;17(12):3458-3471.
19. Herrera GA, Picken MM. Renal diseases associated with plasma cell dyscrasias, amyloidoses,Waldenstrom macroglobulinemia and cryoglobulinemic nephropathies. In: Jennette JC, Olson JL, Schwartz MM, Silva FG, eds. Heptinstall's Pathology of the Kidney. 6th ed. Philadelphia, PA: Lippincott-Raven; 2006:853-910.
20. Picken MM, Hazenberg BPC, Obici L. Report from the diagnostic interactive session. In: Skinner M, Berk JL, Connors LH, Seldin DC, eds. XIth International Symposium on Amyloidosis. Boca Raton, FL: CRC Press; 2007:377-382.
21. Westermark P, Davey E, Lindbom K, Enquist S. Subcutaneous fat tissue for diagnosis and studies of systemic amyloidosis. Acta Histochem. 2006;108(3): 209-213. (Pubitemid 44015877)
22. van Gameren II, Hazenberg BP, Bijzet J, van Rijswijk MH. Diagnostic accuracy of subcutaneous abdominal fat tissue aspiration for detecting systemic amyloidosis, and its utility in clinical practice. Arthritis Rheum. 2006;54(6):2015-2021. (Pubitemid 43877954)
23. Hazenberg BP, Bijzet J, Limburg PC, et al. Diagnostic performance of amyloid A protein quantification in fat tissue of patients with clinical AA amyloidosis. Amyloid. 2007;14(2):133-140. (Pubitemid 46956918)
24. Kaplan B, Vidal R, Kumar A, Ghiso J, Gallo G. Immunochemical microanalysis of amyloid proteins in fine-needle aspirates of abdominal fat. Am J Clin Pathol. 1999;112(3):403-407. (Pubitemid 30214781)
25. Ryan JG, Kastner DL. Fevers, genes, and innate immunity. Curr Top Microbiol Immunol. 2008;321:169-184.
26. Eriksson M, Schonland S, Bergner R, et al. Three German fibrinogen Aα-chain amyloidosis patients with the p.Glu526Val mutation. Virchows Arch. 2008; 453(1):25-31.
27. Lobato L, Beirao I, Silva M, et al. End-stage renal disease and dialysis in hereditary amyloidosis TTR V30M: presentation, survival and prognostic factors. Amyloid. 2004;11(1):27-37. (Pubitemid 38680236)
28. Korbet SM, Bonsib S. A case of polyneuropathy and proteinuria. Clin J Am Soc Nephrol. 2008;3(2):624-636.
29. Eriksson M, Buttner J, Todorov T, et al. Prevalence of germline mutations in the TTR gene in a consecutive series of surgical pathology specimens with ATTR amyloid. Am J Surg Pathol. 2009;33(1):58-65.
30. Haagsma EB, Hawkins PN, Benson MD, et al. Familial amyloidotic polyneuropathy with severe renal involvement in association with transthyretin Gly47Glu in Dutch, British and American-Finnish families. Amyloid. 2004;11(1): 44-49.
31. Gillmore JD, Lachmann HJ, Rowczenio D, et al. Diagnosis, pathogenesis treatment, and prognosis of hereditary fibrinogen A alpha-chain amyloidosis. J Am Soc Nephrol. 2009;20(2):444-451.
32. Picken MM, Linke RP. Nephrotic syndrome due to an amyloidogenic mutation in fibrinogen A alpha chain. J Am Soc Nephrol. 2009;20(8):1681-1685.
33. Gregorini G, Izzi C, Obici L, et al. Renal apolipoprotein A-I amyloidosis: a rare and usually ignored cause of hereditary tubulointerstitial nephritis. J Am Soc Nephrol. 2005;16(12):3680-3686. (Pubitemid 46211289)
34. Granel B, Valleix S, Serratrice J, et al. Lysozyme amyloidosis: report of 4 cases and a review of the literature. Medicine. 2006;85(1):66-73. (Pubitemid 43884289)
35. Lachmann HJ, Booth DR, Booth SE, et al. Misdiagnosis of hereditary amyloidosis as AL (primary) amyloidosis. N Engl J Med. 2002;346(23):1786-1791.
36. Landau H, Comenzo RL, Zhou P, et al. AL amyloidosis in a patient with a T60A TTR mutation. Amyloid. 2006;13(suppl 1):40.
37. Comenzo RL, Zhou P, Fleisher M, et al. Seeking confidence in the diagnosis of systemic AL (Ig light chain) amyloidosis: patients can have both monoclonal gammopathies and hereditary amyloid proteins. Blood. 2006;107(9):3489-3491.
38. Wechalekar AD, Offer M, Gillmore JD, Hawkins PN, Lachmann HJ. Cardiac amyloidosis, a monoclonal gammopathy and a potentially misleading mutation. Nat Clin Pract Cardiovasc Med. 2009;6(2):128-133.
39. Ng B, Connors LH, Davidoff R, et al. Senile systemic amyloidosis presenting with heart failure. Arch Intern Med. 2005;165(12):1425-1429.
40. Picken MM. Immunoglobulin light and heavy chain amyloid: renal pathology and differential diagnosis. In: Herrera GA, ed. The Kidney in Plasma Cell Dyscrasias. Basel, Switzerland: Karger; 2007;153:135-155.
41. Novak L, Cook WJ, Herrera GA, et al. AL-amyloidosis is underdiagnosed in renal biopsies. Nephrol Dial Transplant. 2004;19(12):3050-3053. (Pubitemid 40057627)
42. Picken MM. Amyloid typing in surgical pathology: experience of a single institution. In: Skinner M, Berk JL, Connors LH, Seldin DC, eds. XIth International Symposium on Amyloidosis. Boca Raton, FL: CRC Press; 2007:289-291.
43. Satoskar AA, Burdge K, Cowden DJ, Nadasdy GM, Hebert LA, Nadasdy T. Typing of amyloidosis in renal biopsies: diagnostic pitfalls. Arch Pathol Lab Med. 2007;131(6):917-922. (Pubitemid 46906383)
44. Kebbel A, Rocken C. Immunohistochemical classification of amyloid in surgical pathology revisited. Am J Surg Pathol. 2006;30(6):673-683. (Pubitemid 44264992)
45. Linke RP, Oos R, Wiegel NM, Nathrath WB. Classification of amyloidosis: misdiagnosing by way of incomplete immunohistochemistry and how to prevent it. Acta Histochem. 2006;108(3):197-208. (Pubitemid 44015876)
46. Arbustini E, Verga L, Concardi M, Palladini G, Obici L, Merlini G. Electron and immuno-electron microscopy of abdominal fat identifies and characterizes amyloid fibrils in suspected cardiac amyloidosis. Amyloid. 2002;9(2):108-114. (Pubitemid 34787804)
47. Kuci H, Ebert MP, Rocken C. Anti-lambda-light chain-peptide antibodies are suitable for the immunohistochemical classification of AL amyloid. Histol Histopathol. 2007;22(4):379-387. (Pubitemid 46647251)
48. Kaplan B, Martin BM, Livneh A, et al. Biochemical subtyping of amyloid in formalin-fixed tissue samples confirms and supplements immunohistologic data. Am J Clin Pathol. 2004;121(6):794-800. (Pubitemid 38669271)
49. Murphy CL, Eulitz M, Hrncic R, et al. Chemical typing of amyloid protein contained in formalin-fixed paraffin-embedded biopsy specimens. Am J Clin Pathol. 2001;116(1):135-142. (Pubitemid 32601138)
50. Goni F, Gallo G. Extraction and chemical characterization of tissue-deposited proteins from minute diagnostic biopsy specimens. Methods Mol Biol. 2005;299:261-266.
51. Murphy CL, Wang S, Williams T, et al. Characterization of systemic amyloid deposits by mass spectrometry. Methods Enzymol. 2006;412:48-62. (Pubitemid 44548573)
52. Picken RN, Morgan M, Picken MM. Detection of cardiac pre-amyloid deposits of transthyretin by MALDI-TOF. In: Skinner M, Berk JL, Connors LH, Seldin DC, eds. XIth International Symposium on Amyloidosis. Boca Raton, FL: CRC Press; 2007:182-184.
53. Lavatelli F, Perlman DH, Spencer B, et al. Amyloidogenic and associated proteins in systemic amyloidosis proteome of adipose tissue. Mol Cell Proteomics. 2008;7(8):1570-1583.
54. Solomon A, Murphy CL, Westermark P. Misclassification of amyloidosis is unwarranted. Blood. 2006;108(2):776.
55. Picken MM, Herrera GA. The burden of "sticky" amyloid: typing challenges. Arch Pathol Lab Med. 2007;131(6):850-851.
56. Comenzo RL. Constraints on the pursuit of diagnostic confidence. Blood. 2006;108(2):776-777.